Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMILIA phase II study of daratumumab maintenance duration in light-chain amyloidosis
MOH_2026-01-15_015605Phase 2Not yet recruiting
- Sponsor
- אלי מוכתר
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daratumumab in light-chain amyloidosis (2 arms), sponsored by אלי מוכתר. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2026-01-15_015605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-15_015605.